This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
DANVERS, Mass., Oct. 23, 2012 (GLOBE NEWSWIRE) --
Abiomed,Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced clinical updates on its Symphony™ device, including the second successful human use of Symphony in Canada. The procedure was performed by Renzo Cecere, M.D., Director of the Mechanical Assist Program and Surgical Director of the Heart Failure and Heart Transplant Program at the McGill University Health Centre (MUHC) in Montreal, Quebec.
The Symphony device is a minimally invasive implantable heart pump designed to slow the progression of heart failure and help the heart remodel. The first two patient experiences have been positive and informative for the future promise of the therapy. In both patients, an improvement was immediately demonstrated in overall hemodynamics and physical functionality based on support via the subclavian artery through a non sternotomy, "pacemaker-like" implantation technique.
Both patients were implanted at the MUHC by Dr. Renzo Cecere. This newest patient received Symphony in September 2012 and was successfully explanted as planned after 28 days of therapy.
"We were extremely pleased with the patient's overall improvement and the Symphony's performance over 28 days of continuous therapy," said Dr. Cecere. "We look forward to the ongoing development of this program with additional patients in the coming months."
Additionally, Abiomed recently received ANSM (Agence Nationale de Sécurité du Médicament) approval in France, enabling the use of Symphony in clinical trials. Currently, a select number of hospitals in France are training to implant the Symphony device in clinical investigations.
"We are encouraged to learn of the second patient's results with Symphony and believe this unique implantable heart pump will offer a minimally invasive, cost-effective approach to improve hemodynamics for these types of chronic heart failure patients. We look forward to continued clinical progress in Canada and France," said Michael R. Minogue, Chairman, President, and Chief Executive Officer of Abiomed.